TY - PAT
T1 - Alginate Compositions and Uses Thereof
AU - Cohen, Smadar
AU - Ilan, Yaron
AU - Shteyer, Eyal
AU - Ben-Ya'acov, Ami
N1 - US Patent 10,500,226
PY - 2019/12/10
Y1 - 2019/12/10
N2 - Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than −25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10−8 cm2/second, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease; liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.
AB - Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than −25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10−8 cm2/second, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease; liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.
M3 - Patent
M1 - US10500226B2
ER -